Opinions & Features

Now that Theranos faces the prospect of a crippling ban on its operations by federal officials, let’s get past its implosion and talk about the real implications for the rest of the diagnostic sector.

It’s not often that we see the collapse of a large pharmaceutical company in real time.

The gloom at the J.P. Morgan 34th annual healthcare conference in San Francisco last week is still thick in the air – and will likely to hover there for a while, as macro issues and[...]

With a continuing weekly newsfeed on the destructive conse- quences of inadequate mental healthcare and with growing data on how depression negatively impacts the ability to perform daily tasks and engage in social interactions, why[...]

The arrest of Martin Shkreli for securities fraud involving alleged misuses of funds from his former company, Retrophin Inc., raises more questions than it answers–and as the case plays out in federal court this gap[...]

It couldn’t have been easy for Elizabeth Holmes, CEO & founder of the controversial blood test company Theranos, to prepare for an interview with Matt Herper at the Forbes Healthcare Summit.

All eyes are fixed on the declared merger of Pfizer, Inc. and Allergan plc, which has the impact of an inversion, and the questions quickly become: Is it a game changer, a challenge to Treasury’s[...]

The history of holidays in the United States has been to turn religious, national, or social occasions into revenue opportunities.

Valeant Pharmaceuticals is making headlines again as news continues to drip out on its business practices. Recently reports emerged that Valeant, a hedge fund darling, has the option right to acquire a private company called[...]

Insurance companies have a major stake in the national discussion on the cost of drugs. They’re usually pitted against big pharma and biotech, looking for ways to save money on care and drugs. One recent[...]